在埃塞俄比亚西北部Debre Markos综合专科医院接受以dolutegravvir为基础的抗逆转录病毒治疗的HIV感染者中血脂异常及其相关因素:一项横断面研究

IF 1.8 Q4 INFECTIOUS DISEASES
AIDS Research and Treatment Pub Date : 2025-08-05 eCollection Date: 2025-01-01 DOI:10.1155/arat/6621097
Mohammed Jemal, Adane Adugna, Mamaru Getinet, Baye Ashenef, Gelagey Baye, Desalegn Abebaw, Zigale Hibstu Teffera, Wastina Bitewlign, Anemut Tilahun, Nuredin Chura Waritu, Tabarak Malik, Enyew Fenta Mengistu
{"title":"在埃塞俄比亚西北部Debre Markos综合专科医院接受以dolutegravvir为基础的抗逆转录病毒治疗的HIV感染者中血脂异常及其相关因素:一项横断面研究","authors":"Mohammed Jemal, Adane Adugna, Mamaru Getinet, Baye Ashenef, Gelagey Baye, Desalegn Abebaw, Zigale Hibstu Teffera, Wastina Bitewlign, Anemut Tilahun, Nuredin Chura Waritu, Tabarak Malik, Enyew Fenta Mengistu","doi":"10.1155/arat/6621097","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Dyslipidemia is a prevalent public health concern among individuals living with HIV who are undergoing antiretroviral therapy (ART), and it increases the risk of cardiovascular diseases. Despite the introduction of improved medications like dolutegravir, there are limited data regarding the extent of dyslipidemia in this population. Therefore, the purpose of this study was to determine the prevalence of dyslipidemia and its associated factors among people living with HIV on dolutegravir-based ART. <b>Methods:</b> An institutional-based cross-sectional study was carried out from December 1, 2021, to February 30, 2022. Sociodemographic, behavioral, clinical, anthropometric, and laboratory data were collected from 423 participants. Simple random sampling methods were used to recruit the participants. The collected data were entered in Epi-data Version 4.6 and analyzed via SPSS Version 26. Multivariable logistic regression was used to determine factors associated with dyslipidemia. A <i>p</i> value of < 0.05 was considered statistically significant. <b>Results:</b> The prevalence of dyslipidemia was found to be 73.8%. Low HDL-C was the most common (61.2%), followed by elevated levels of TG (40.2%), high LDL-C (26%), and high TC (24.3%). Being female (AOR = 1.77, 95% CI: 1.04-3.02, <i>p</i>=0.034), insufficient physical activity (AOR = 1.64, 95% CI: 1-2.67, <i>p</i>=0.048), being overweight (AOR = 2.25, 95% CI: 1.07-4.75, <i>p</i>=0.033), and being obese (AOR = 2.32, 95% CI: 0.86-6.25, <i>p</i>=0.045) were significantly associated with dyslipidemia. <b>Conclusion:</b> The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants. Being female, insufficient physical activity, and being overweight or obese were significantly associated with dyslipidemia among people living with HIV taking dolutegravir-based ART. Therefore, to avoid the disastrous effects of dyslipidemia, serum lipid profiles should be considered and evaluated in people living with HIV on a dolutegravir-based ART.</p>","PeriodicalId":46303,"journal":{"name":"AIDS Research and Treatment","volume":"2025 ","pages":"6621097"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343171/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study.\",\"authors\":\"Mohammed Jemal, Adane Adugna, Mamaru Getinet, Baye Ashenef, Gelagey Baye, Desalegn Abebaw, Zigale Hibstu Teffera, Wastina Bitewlign, Anemut Tilahun, Nuredin Chura Waritu, Tabarak Malik, Enyew Fenta Mengistu\",\"doi\":\"10.1155/arat/6621097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Dyslipidemia is a prevalent public health concern among individuals living with HIV who are undergoing antiretroviral therapy (ART), and it increases the risk of cardiovascular diseases. Despite the introduction of improved medications like dolutegravir, there are limited data regarding the extent of dyslipidemia in this population. Therefore, the purpose of this study was to determine the prevalence of dyslipidemia and its associated factors among people living with HIV on dolutegravir-based ART. <b>Methods:</b> An institutional-based cross-sectional study was carried out from December 1, 2021, to February 30, 2022. Sociodemographic, behavioral, clinical, anthropometric, and laboratory data were collected from 423 participants. Simple random sampling methods were used to recruit the participants. The collected data were entered in Epi-data Version 4.6 and analyzed via SPSS Version 26. Multivariable logistic regression was used to determine factors associated with dyslipidemia. A <i>p</i> value of < 0.05 was considered statistically significant. <b>Results:</b> The prevalence of dyslipidemia was found to be 73.8%. Low HDL-C was the most common (61.2%), followed by elevated levels of TG (40.2%), high LDL-C (26%), and high TC (24.3%). Being female (AOR = 1.77, 95% CI: 1.04-3.02, <i>p</i>=0.034), insufficient physical activity (AOR = 1.64, 95% CI: 1-2.67, <i>p</i>=0.048), being overweight (AOR = 2.25, 95% CI: 1.07-4.75, <i>p</i>=0.033), and being obese (AOR = 2.32, 95% CI: 0.86-6.25, <i>p</i>=0.045) were significantly associated with dyslipidemia. <b>Conclusion:</b> The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants. Being female, insufficient physical activity, and being overweight or obese were significantly associated with dyslipidemia among people living with HIV taking dolutegravir-based ART. Therefore, to avoid the disastrous effects of dyslipidemia, serum lipid profiles should be considered and evaluated in people living with HIV on a dolutegravir-based ART.</p>\",\"PeriodicalId\":46303,\"journal\":{\"name\":\"AIDS Research and Treatment\",\"volume\":\"2025 \",\"pages\":\"6621097\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343171/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS Research and Treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/arat/6621097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/arat/6621097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:在接受抗逆转录病毒治疗(ART)的艾滋病毒感染者中,血脂异常是一个普遍的公共卫生问题,它增加了心血管疾病的风险。尽管引进了改进的药物,如多替格拉韦,但关于这一人群中血脂异常程度的数据有限。因此,本研究的目的是确定接受以盐酸孕酮为基础的抗逆转录病毒治疗的艾滋病毒感染者中血脂异常的患病率及其相关因素。方法:于2021年12月1日至2022年2月30日进行基于机构的横断面研究。从423名参与者中收集了社会人口学、行为学、临床、人体测量学和实验室数据。采用简单的随机抽样方法招募参与者。收集的数据在Epi-data Version 4.6中录入,并通过SPSS Version 26进行分析。采用多变量logistic回归确定与血脂异常相关的因素。p值< 0.05认为有统计学意义。结果:血脂异常患病率为73.8%。低HDL-C是最常见的(61.2%),其次是高TG(40.2%),高LDL-C(26%)和高TC(24.3%)。女性(AOR = 1.77, 95% CI: 1.04-3.02, p=0.034)、身体活动不足(AOR = 1.64, 95% CI: 1-2.67, p=0.048)、超重(AOR = 2.25, 95% CI: 1.07-4.75, p=0.033)和肥胖(AOR = 2.32, 95% CI: 0.86-6.25, p=0.045)与血脂异常显著相关。结论:在接受以盐酸孕酮为基础的抗逆转录病毒治疗的艾滋病毒感染者中,血脂异常的患病率很高,发生在近四分之三的参与者中。女性、身体活动不足、超重或肥胖与接受以盐酸孕酮为基础的抗逆转录病毒治疗的艾滋病毒感染者的血脂异常显著相关。因此,为了避免血脂异常的灾难性影响,应考虑和评估使用以母体母体为基础的抗逆转录病毒治疗的艾滋病毒感染者的血脂谱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study.

Background: Dyslipidemia is a prevalent public health concern among individuals living with HIV who are undergoing antiretroviral therapy (ART), and it increases the risk of cardiovascular diseases. Despite the introduction of improved medications like dolutegravir, there are limited data regarding the extent of dyslipidemia in this population. Therefore, the purpose of this study was to determine the prevalence of dyslipidemia and its associated factors among people living with HIV on dolutegravir-based ART. Methods: An institutional-based cross-sectional study was carried out from December 1, 2021, to February 30, 2022. Sociodemographic, behavioral, clinical, anthropometric, and laboratory data were collected from 423 participants. Simple random sampling methods were used to recruit the participants. The collected data were entered in Epi-data Version 4.6 and analyzed via SPSS Version 26. Multivariable logistic regression was used to determine factors associated with dyslipidemia. A p value of < 0.05 was considered statistically significant. Results: The prevalence of dyslipidemia was found to be 73.8%. Low HDL-C was the most common (61.2%), followed by elevated levels of TG (40.2%), high LDL-C (26%), and high TC (24.3%). Being female (AOR = 1.77, 95% CI: 1.04-3.02, p=0.034), insufficient physical activity (AOR = 1.64, 95% CI: 1-2.67, p=0.048), being overweight (AOR = 2.25, 95% CI: 1.07-4.75, p=0.033), and being obese (AOR = 2.32, 95% CI: 0.86-6.25, p=0.045) were significantly associated with dyslipidemia. Conclusion: The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants. Being female, insufficient physical activity, and being overweight or obese were significantly associated with dyslipidemia among people living with HIV taking dolutegravir-based ART. Therefore, to avoid the disastrous effects of dyslipidemia, serum lipid profiles should be considered and evaluated in people living with HIV on a dolutegravir-based ART.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AIDS Research and Treatment
AIDS Research and Treatment INFECTIOUS DISEASES-
CiteScore
3.10
自引率
0.00%
发文量
13
审稿时长
18 weeks
期刊介绍: AIDS Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focused on all aspects of HIV and AIDS, from the molecular basis of disease to translational and clinical research. In addition, articles relating to prevention, education, and behavior change will be considered
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信